resTORbio (NASDAQ:TORC) Upgraded to “Buy” at ValuEngine
Other analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of resTORbio from a hold rating to a sell rating in a research note on Tuesday, August 20th. Cantor Fitzgerald initiated coverage on shares of resTORbio in a research note on Monday. They issued an overweight rating and a $23.00 price objective for the company. Finally, Guggenheim initiated coverage on shares of resTORbio in a research note on Tuesday, June 4th. They issued a buy rating and a $28.00 price objective for the company. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $20.67.
NASDAQ TORC traded up $0.13 during trading on Thursday, hitting $10.27. The stock had a trading volume of 1,513 shares, compared to its average volume of 111,229. The stock has a market capitalization of $375.60 million, a price-to-earnings ratio of -7.30 and a beta of 3.30. resTORbio has a one year low of $6.21 and a one year high of $16.66. The stock has a 50 day simple moving average of $9.96 and a 200 day simple moving average of $8.77.
Several institutional investors have recently bought and sold shares of TORC. Invesco Ltd. bought a new stake in shares of resTORbio during the second quarter valued at approximately $44,052,000. OppenheimerFunds Inc. bought a new stake in shares of resTORbio during the first quarter valued at approximately $29,440,000. Jennison Associates LLC raised its stake in shares of resTORbio by 34.0% during the first quarter. Jennison Associates LLC now owns 2,868,640 shares of the company’s stock valued at $19,564,000 after acquiring an additional 728,566 shares in the last quarter. BlackRock Inc. raised its stake in shares of resTORbio by 72.9% during the second quarter. BlackRock Inc. now owns 1,383,763 shares of the company’s stock valued at $14,115,000 after acquiring an additional 583,233 shares in the last quarter. Finally, FMR LLC bought a new stake in shares of resTORbio during the first quarter valued at approximately $2,453,000. 62.96% of the stock is owned by hedge funds and other institutional investors.
resTORbio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems.
Read More: Do You Need a Fiduciary?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for resTORbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for resTORbio and related companies with MarketBeat.com's FREE daily email newsletter.